IP Library › Granted Patent US 12,502,407
Granted Patent B2
US 12,502,407 · App. 19/205,490 · Granted Dec 23, 2025

Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles

Inventors: Timothy Alexander Moseley (Fallbrook, CA); Kenneth Allen Pettine (Fort Collins, CO)
Assignee: Direct Biologics, LLC
A61K35/28C12N5/0663C12N2500/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,407
App. No.
19/205,490
Granted
Dec 23, 2025
Kind
B2
Abstract

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Claims (24)

1 . A method of treating perianal fistula in a subject having ulcerative colitis or Crohn's disease, the method comprising administering to the subject a therapeutic bone marrow MSC secretome composition comprising extracellular vesicles, wherein at least 80% of the extracellular vesicles are CD63 + CD9 − CD81 − .

2 . The method of claim 1 , wherein the perianal fistula is a cryptoglandular perianal fistula.

3 . The method of claim 1 , wherein the administering comprises an injection or parenteral administration.

4 . The method of claim 3 , wherein the injection comprises one or more injections into a tissue surrounding the perianal fistula.

5 . The method of claim 3 , wherein the parenteral administration comprises a slow release or sustained release system that maintains a constant dosage.

6 . The method of claim 1 , wherein the therapeutic bone marrow MSC secretome composition has a cell-equivalent dosage of 0.7 to 7 million cells/kg.

7 . The method of claim 1 , wherein the therapeutic bone marrow MSC secretome composition has 5×10 11 to 1.5×10 12 extracellular vesicles.

8 . The method of claim 1 , wherein the therapeutic bone marrow MSC secretome composition has 6×10 10 to 8×10 10 extracellular vesicles per mL.

9 . The method of claim 8 , wherein the therapeutic bone marrow MSC secretome composition is administered to the subject at a dose of 10 to 30 mL.

10 . The method of claim 1 , wherein the subject has had a previous failed surgical treatment of a perianal fistula.

11 . The method of claim 1 , wherein the subject has had a seton placement at least 2 weeks before the administering.

12 . The method of claim 1 , wherein the therapeutic bone marrow MSC secretome composition comprises one or more of the following proteins: 2B4, 4-1BB, 4-1BB Ligand, 6Ckine, ACE, Activin A, Activin RIB, Activin RIIA, Activin RIM, ADA, ADAM23, ADAMS, ADAMTS13, ADAMTSL-1, Adiponectin, Adipsin, Aggrecan, AgRP, AIF, AKR1C4, Albumin, ALCAM, AMIGO, AMIGO2, Aminopeptidase LRAP, Aminopeptidase P2, AMSH, ANG-1, ANG-2, ANG-4, Angiogenin, Angiotensinogen, ANGPTL4, ANGPTL7, APRIL, Arginase 1, ARSB, Artemin, Arylsulfatase A, ASAH2, ASAHL, Ax1, B2M, B7-1, B7-H3, B7-H4, BAFF R, BCL-10, BCL-2, BCL-w, BCMA, BID, bIG-H3, Biglycan, BLAME, BMP-2, BMP-8, BMP-9, BMPR-IA, Brevican, CA125, CA13, CA2, CA4, CA8, Cadherin-13, Cadherin-4, Calreticulin, Calreticulin-2, Cardiotrophin-1, CASA, Caspr2, Cathepsin B, Cathepsin E, Cathepsin L, Cathepsin S, Cathepsin V, CD109, CD14, CD155, CD157, CD2, CD200, CD229, CD27, CD27 Ligand, CD28, CD30, CD300f, CD314, CD34, CD36, CD39L2, CD4, CD40, CD40L, CD42b, CD48, CD51, CD58, CD6, CD63, CD73, CD81, CD83, CD9, CD97, CD99, CD99-L2, CDC25B, CDNF, CDS, CEACAM-1, CEACAM-3, CEACAM-5, Cerberus 1, CES1, CES2, CF VII, CF XIV, Chemerin, CHI3L1, CHST2, CHST3, CHST4, cIAP-1, cIAP-1, CILP-1, CK19, CLEC-1, CLEC10A, CLEC-2, CL-P1, Clq, ClqTNF9, cMASP3, CMG-2, C-myc, CNTF, Cochlin, COMT, Contactin-1, Contactin-2, CPB1, CPE, CREG, CRELD2, CRIM1, CrkL, CSa, CTACK, CTRC, CXCL14, CXCL16, Cyr61, Cystatin B, Cystatin C, Cystatin D, Cystatin E M, Cystatin S, Cystatin SA, Cystatin SN, Cytokeratin-8, DAPP1, DcR3, DCTN1, DDR1, Decorin, Dectin-1, Dectin-2, Desmin, Desmoglein 2, Desmoglein-3, DKK-1, DKK-3, DKK-3, DLL4, DNAM-1, DNMT3A, Dopa Decarboxylase, DPPII, DPPIV, DR3, DR6, Nogo Receptor, Draxin, DSCAM, DSPG3, Dtk, EDAR, EDIL3, EGF R, EG-VEGF, EMMPRIN, Endocan, Endoglin, ENA-78, Endoglycan, eNOS, ENPP-2, ENPP-7, Enteropeptidase, EpCAM, EphA1, EphA2, EphB3, EphB4, EphB6, Ephrin-A4, Ephrin-B3, Epimorphin, Epiregulin, ErbB3, ErbB4, Erythropoietin, ESAM, E-Selectin, EXTL3, FABP1, FABP2, FABP4, FABP6, FAP, Fas, FCAR, FcERI, FCRL1, FCRL3, FCRLB, FCRLS, Ferritin, FGF R5, FGF-12, FGF-16, FGF-17, FGF-19, FGF-20, FGF-21, FGF-23, FGF-3, FGF-5, Ficolin-1, FKBP51, FLRG, FLRT1, FLRT2, Flt-3, Flt-3L, Follistatin, Follistatin-like 1, Furin, FUT8, Galanin, Galectin-1, Galectin-2, Galectin-3, Galectin-4, Galectin-7, Galectin-8, Galectin-9, GALNT10, GALNT2, GALNT3, Gash, GATA-4, GBA3, GCP-2, GDF-11, GDF-15, GDF-9, GFAP, GFR alpha-1, GFR alpha-2, GITR, GITR L, GKN1, GLP-1, Glycoprotein V, Glyoxalase II, Glypican 1, Glypican 2, Glypican 5, GM-CSF Ra, gp130, GP73, GPR115, GPR56, GPVI, Granulysin, Granzyme A, Granzyme B, Granzyme H, GRAP2, GRKS, GRO, GSTM1, GUSB, HAO-1, HAPLN1, HCC-1, HCC-4, hCGb, HE4, Hepsin, HGF, HGF R, HIF-1 alpha, HIF-1 beta, HO-1, HS3ST1, HS3ST3B1, HS3ST4, HSD17B1, htPAPP-A, HTRA2, HVEM, ICAM-1, ICAM-2, ICAM-3, ICOS, IDO, IFNab R2, IFNb, IFN-gamma R1, IGF-2, IGF-2R, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-5, IGFBP-6, IGSF3, IGSF4B, IL-1 F10, IL-1 R3, IL-1 R4, IL-1 R6, IL-1 RI, IL-1 RII, IL-10 Rb, IL-12p40, IL-13, IL-13 R2, IL-15, IL-15 R, IL-17 RC, IL-17 RD, IL-17B, IL-17F, IL-18, IL-18 BPa, IL-19, IL-2 Ra, IL-2 Rb, IL-2 Rg, IL-20 R beta, IL-20 Ra, IL-21 R, IL-22, IL-22 R alpha 1, IL-22 BP, IL-23, IL-23 R, IL-24, IL-27, IL-27 Ra, IL-28 R alpha, IL-28A, IL-31, IL-31 RA, IL-32 alpha, IL-33, IL-4 Ra, IL-6, IL-6 R, IL-7 R alpha, IL-8, IL-9, IL-1ra, ILT2, ILT4, Inhibin A, Insulin, Insulin R, Integrin alpha 1, Integrin alpha 5, IP-10, I-TAC, Jagged 1, JAM-A, JAM-B, JAM-C, Kallikrein 1, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 5, Kallikrein 7, Kell, KIR2DL3, Kirrel3, KLF4, Kremen-2, Kynureninase, L1CAM-2, LAIR2, LAMA4, LAMP, LAMP1, LAMP2, Langerin, LAP(TGFb1), LDL R, LEDGF, Legumain, LH, LIF, LIF R alpha, LIGHT, LILRB4, LIMPII, Lin28, Lipocalin-2, LOX-1, LRP-6, LRRC4, LRRTM4, LSECtin, L-Selectin, LTbR, Lumican, Lymphotactin, LYVE-1, MAP1D, Matrilin-2, Matrilin-3, Matriptase, MBL, Mc1-1, MCEMP1, MCP-2, MCP-3, MCP-4, MCSF, MDC, MDL-1, MEF2C, MEP1B, MEPE, MeprinA, Mer, Mesothelin, METAP2, MFRP, MIA, MICA, MICB, Midkine, MIF, MIP-3a, MIP-3b, MIP-lb, MIS RII, MMP-1, MMP-10, MMP-12, MMP-13, MMP-2, MOG, MPIF-1, MSP, MSP R, NAP-2, N-Cadherin, NCAM-1 (CD56), NCK1, Nectin-1, Nectin-2, Nectin-3, Nectin-4, Neprilysin, Nestin, Netrin-4, Neudesin, Neurexin 3 beta, Neurogranin, Neuroligin 2, Neurturin, NG2, NGF R, Nidogen-1, Nidogen-2, NKp30, NKp44, NKp46, NKp80, Nogo-A, Norrin, Notch-1, Notch-3, NOV, NPDC-1, NPTXR, NQO-1, Nrf2, NRG1-131, NSE, NTAL, NUDTS, Numb, NUP85, Olfactomedin-2, Olig2, OPG, OPN, OSCAR, OSM R beta, Osteoactivin, Osteoadherin, OX40, OX40 Ligand, PlGF-2, p2'7, p53, p63, PAI-1, PAPP-A, Pappalysin-2, PAR1, PARC, Pax3, PCK1, PCSK2, PD-1, PD-ECGF, PDGF R alpha, PDGF Rb, PDGF-AA, PDGF-AB, PDGF-CC, PD-L2, PDX-1, PEAR1, PECAM-1, Pentraxin 3, Pepsinogen II, Periostin, Persephin, PF4, PGRP-S, PIGF, PILR-alpha, Plexin A4, Plexin B3, Plexin D1, Podocalyxin, Podoplanin, POGLUT1, PON1, PRDX4, Pref-1, PRELP, Presenilin 1, Procalcitonin, Progranulin, proGRP, Prolactin, Prolactin R, PRX2, PSA-total, PSMA, PSMA1, PTH, PTH1R, PTP1B, PU.1, PYY, RAGE, RalA, RANK RANTES, RBP4, RCOR1, Reg3A, Reg4, RELT, Renin, Resistin, Ret Midkine, RGM-A, RGM-B, RGM-C, ROBO2, ROBO3, ROBO4, ROR1, ROR2, R-Spondin 2, S100A1, S100A13, SALM4, SCCA2, SCF, SCF R, SDF-la, SDF-lb, Semaphorin 4C, Semaphorin 4D, Semaphorin 4G, Semaphorin 6A, Semaphorin 6B, Semaphorin 6C, Semaphorin 6D, Semaphorin 7A, Serpin A4, Serpin A5, Serpin B6, Serpin Fl, sFRP-3, SH2D1A, Shh-N, SHP-1, Siglec-10, Siglec-11, Siglec-2, Siglec-6, Siglec-7, Siglec-9, SIRP alpha, Sirtuin 1, Sirtuin 2, Sirtuin 5, SLAM, SLITRK5, Smad4, SMPD1, SorCS1, SorCS2, SorCS3, Sortilin, SOST, SOX15, SOX2, SOX7, SOX9, SP-D, SPHK1, Spinesin, SPINK1, SR-AI, SREC-I, SREC-II, ST3GAL1, ST6GAL1, ST8SIA1, Stabilin-2, SULT2A1, Syndecan-3, Syndecan-4, Syntaxin 4, Syntaxin 6, TACE, TAFA1, TAFA2, TAFAS, TARC, TAZ, TCN2, TC-PTP, TECK, Tenascin R, Testican 2, TFF3, TFPI, TFPI-2, TGFa, TGFb2, TGFb3 FOLR2, TGFbl, TGM3, TGM4, THAP11, Thrombomodulin, Thrombospondin-2, Thrombospondin-5, THSD1, Thyroglobulin, Thyroid Peroxidase, Tie-1, Tie-2, TIM-1, TIM-3, TIMP-1, TIMP-2, TLR1, TLR2, TLR3, TLR4, TNF RI, TNF RII, TNF4, TNFb, TPO, TPP1, TPST2, TRACP, TRAIL, TRAIL R1, TRAIL R3, TRAIL R4, TRANCE, Transferrin, TREM-1, TREM-2, TREML1, TrkC, TROP-2, Troponin C, TROY, Trypsin 1, Trypsin 3, TSH, TSK, TSLP, TSLP R, TSP-1, TWEAK R, Ubiquitin+1, UCH-L3, ULBP-1, ULBP-2, ULBP-3, ULBP-4, UNC5H3, UNC5H4, uPA, uPAR, Uromodulin, VAMP-1, VAMP-2, VAP-A, VCAM-1, VE-Cadherin, VEGF, VEGF R1, VEGF R2, VEGF R3, VEGF-C, Visfatin, vWF-A2, WIF-1, WISP-1, Wnt-4, XEDAR, and XIAP.

13 . The method of claim 1 , wherein the therapeutic bone marrow MSC secretome composition comprises one or more of the following nucleic acids: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-3p, hsa-let-7e-5p, hsa-let-7g-5p, hsa-let-7i, hsa-let-7i-5p, hsa-miR-100-5p, hsa-miR-103a-3p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-mir-10b, hsa-miR-10b-5p, hsa-mir-1246, hsa-miR-1246, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-130a-3p, hsa-mir-130b, hsa-miR-130b-3p, hsa-miR-132-3p, hsa-miR-136-5p, hsa-miR-138-5p, hsa-miR-139-5p, hsa-mir-140, hsa-miR-l 40-3p, hsa-miR-145-5p, hsa-mir-146a, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-152-3p, hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-mir-16-1, hsa-miR-16-2, hsa-miR-16-5p, hsa-miR-1'7-5p, hsa-miR-181a-5p, hsa-miR-191-5p, hsa-miR-193a-5p, hsa-miR-193b-3p, hsa-miR-19'7-3p, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, hsa-mir-203a, hsa-miR-203a-3p, hsa-miR-214-3p, hsa-mir-21, hsa-miR-21-3p, hsa-miR-21-5p, hsa-mir-221, hsa-miR-221-3p, hsa-mir-222, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-mir-24-1, hsa-mir-24-2, hsa-miR-24-3p, hsa-mir-25, hsa-miR-25-3p, hsa-miR-26a-5p, hsa-miR-27a-3p, hsa-mir-27b, hsa-miR-27b-3p, hsa-miR-29a-3p, hsa-miR-29c-3p, hsa-miR-30a-5p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-30d, hsa-miR-30d-5p, hsa-mir-30e, hsa-miR-30e-5p, hsa-miR-3 l-3p, hsa-miR-3 l-5p, hsa-miR-320a, hsa-miR-342-3p, hsa-miR-345-5p, hsa-miR-34a-5p, hsa-miR-361-5p, hsa-miR-376a-3p, hsa-miR-376c-3p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-424-5p, hsa-miR-484, hsa-mir-486-1, hsa-mir-486-2, hsa-miR-486-5p, hsa-miR-570-3p, hsa-miR-574-3p, hsa-miR-663a, hsa-miR-874-3p, hsa-mir-92a-1, hsa-mir-92a-2, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-mir-93, hsa-miR-93-5p, hsa-miR-940, hsa-miR-99a-5p, and hsa-miR-99b-5p.

14 . A method of treating perianal fistula in a subject in need thereof, the method comprising administering to the subject a therapeutic bone marrow MSC secretome composition comprising extracellular vesicles, wherein the therapeutic bone marrow MSC secretome composition comprises VEGF, TIMP1, and IGFBP4.

15 . The method of claim 14 , wherein the therapeutic bone marrow MSC secretome composition further comprises: 2B4, 4-lBB, 4-lBB Ligand, 6Ckine, ACE, Activin A, Activin RIB, Activin RIIA, Activin RIM, ADA, ADAM23, ADAMS, ADAMTS13, ADAMTSL-1, Adiponectin, Adipsin, Aggrecan, AgRP, AIF, AKR1C4, Albumin, ALCAM, AMIGO, AMIGO2, Aminopeptidase LRAP, Aminopeptidase P2, AMSH, ANG-1, ANG-2, ANG-4, Angiogenin, Angiotensinogen, ANGPTL4, ANGPTL 7, APRIL, Arginase 1, ARSB, Artemin, Arylsulfatase A, ASAH2, ASAHL, Ax1, B2M, B7-1, B7-H3, B7-H4, BAFF R, BCL-10, BCL-2, BCL-w, BCMA, BID, bIG-H3, Bigly can, BLAME, BMP-2, BMP-8, BMP-9, BMPR-IA, Brevican, CA125, CA13, CA2, CA4, CA8, Cadherin-13, Cadherin-4, Calreticulin, Calreticulin-2, Cardiotrophin-1, CASA, Caspr2, Cathepsin B, Cathepsin E, Cathepsin L, Cathepsin S, Cathepsin V, CD109, CD14, CD155, CD157, CD2, CD200, CD229, CD27, CD27 Ligand, CD28, CD30, CD300f, CD314, CD34, CD36, CD39L2, CD4, CD40, CD40L, CD42b, CD48, CD51, CD58, CD6, CD63, CD73, CD81, CD83, CD9, CD97, CD99, CD99-L2, CDC25B, CDNF, CDS, CEACAM-1, CEACAM-3, CEACAM-5, Cerberus 1, CES1, CES2, CF VII, CF XIV, Chemerin, CHI3L1, CHST2, CHST3, CHST4, cIAP-1, cIAP-1, CILP-1, CK19, CLEC-1, CLEC10A, CLEC-2, CL-P1, Clq, ClqTNF9, cMASP3, CMG-2, C-myc, CNTF, Cochlin, COMT, Contactin-1, Contactin-2, CPB1, CPE, CREG, CRELD2, CRIM1, CrkL, CSa, CTACK, CTRC, CXCL14, CXCL16, Cyr61, Cystatin B, Cystatin C, Cystatin D, Cystatin EM, Cystatin S, Cystatin SA, Cystatin SN, Cytokeratin-8, DAPP1, DcR3, DCTN1, DDR1, Decorin, Dectin-1, Dectin-2, Desmin, Desmoglein 2, Desmoglein-3, DKK-1, DKK-3, DKK-3, DLL4, DNAM-1, DNMT3A, Dopa Decarboxylase, DPPII, DPPIV, DR3, DR6, Nogo Receptor, Draxin, DSCAM, DSPG3, Dtk, EDAR, EDIL3, EGF R, EG-VEGF, EMMPRIN, Endocan, Endoglin, ENA-78, Endoglycan, eNOS, ENPP-2, ENPP-7, Enteropeptidase, EpCAM, EphA1, EphA2, EphB3, EphB4, EphB6, Ephrin-A4, EphrinB3, Epimorphin, Epiregulin, ErbB3, ErbB4, Erythropoietin, ESAM, E-Selectin, EXTL3, FABP1, FABP2, FABP4, FABP6, FAP, Fas, FCAR, FcERI, FCRL1, FCRL3, FCRLB, FCRLS, Ferritin, FGF RS, FGF-12, FGF-16, FGF-17, FGF-19, FGF-20, FGF-21, FGF-23, FGF-3, FGF-5, Ficolin-1, FKBP51, FLRG, FLRT1, FLRT2, Flt-3, Flt-3L, Follistatin, Follistatin-like 1, Furin, FUT8, Galanin, Galectin-1, Galectin-2, Galectin-3, Galectin-4, Galectin-7, Galectin-8, Galectin-9, GALNT10, GALNT2, GALNT3, Gash, GATA-4, GBA3, GCP-2, GDF-11, GDF-15, GDF-9, GFAP, GFR alpha-1, GFR alpha-2, GITR, GITR L, GKN1, GLP-1, Glycoprotein V, Glyoxalase II, Glypican 1, Glypican 2, Glypican 5, GM-CSF Ra, gp130, GP73, GPR115, GPR56, GPVI, Granulysin, Granzyme A, Granzyme B, GranzymeH, GRAP2, GRKS, GRO, GSTM1, GUSB, HAO-1, HAPLN1, HCC-1, HCC-4, hCGb, HE4, Hepsin, HGF, HGF R, HIF-1 alpha, HIF-1 beta, HO-1, HS3ST1, HS3ST3B1, HS3ST4, HSD17B1, htPAPP-A, HTRA2, HVEM, ICAM-1, ICAM-2, ICAM-3, ICOS, IDO, IFNab R2, IFNb, IFN-gamma R1, IGF-2, IGF-2R, IGFBP-2, IGFBP-3, IGFBP-5, IGFBP-6, IGSF3, IGSF4B, IL-1 F10, IL-1 R3, IL-1 R4, IL-1 R6, IL-1 RI, IL-1 RII, IL-10 Rb, IL-12p40, IL-13, IL-13 R2, IL-15, IL-15 R, IL-17 RC, IL-17 RD, IL-17B, IL-1 7F, IL-18, IL-18 BPa, IL-19, IL-2 Ra, IL-2 Rb, IL-2 Rg, IL-20 R beta, IL-20 Ra, IL-21 R, IL-22, IL-22 R alpha 1, IL-22 BP, IL-23, IL-23 R, IL-24, IL-27, IL-27 Ra, IL-28 R alpha, IL-28A, IL-31, IL-31 RA, IL-32 alpha, IL-33, IL-4 Ra, IL-6, IL-6 R, IL-7 R alpha, IL-8, IL-9, IL-1ra, ILT2, ILT4, Inhibin A, Insulin, Insulin R, Integrin alpha 1, Integrin alpha 5, IP-10, I-TAC, Jagged 1, JAM-A, JAM-B, JAM-C, Kallikrein 1, Kallikrein 11, Kallikrein 12, Kallikrein 14, Kallikrein 5, Kallikrein 7, Kell, KIR2DL3, Kirrel3, KLF4, Kremen-2, Kynureninase, L1CAM-2, LAIR2, LAMA4, LAMP, LAMP1, LAMP2, Langerin, LAP(TGFb1), LDL R, LEDGF, Legumain, LH, LIF, LIF R alpha, LIGHT, LILRB4, LIMPII, Lin28, Lipocalin-2, LOX-1, LRP-6, LRRC4, LRRTM4, LSECtin, L-Selectin, LTbR, Lumican, Lymphotactin, LYVE-1, MAP1D, Matrilin-2, Matrilin-3, Matriptase, MBL, Mc1-1, MCEMP1, MCP-2, MCP-3, MCP-4, MCSF, MDC, MDL-1, MEF2C, MEP1B, MEPE, MeprinA, Mer, Mesothelin, METAP2, MFRP, MIA, MICA, MICB, Midkine, MIF, MIP-3a, MIP-3b, MIP-lb, MIS RII, MMP-1, MMP-10, MMP-12, MMP-13, MMP-2, MOG, MPIF-1, MSP, MSP R, NAP-2, N-Cadherin, NCAM-1 (CD56), NCK1, Nectin-1, Nectin-2, Nectin-3, Nectin-4, Neprilysin, Nestin, Netrin-4, Neudesin, Neurexin 3 beta, Neurogranin, Neuroligin 2, Neurturin, NG2, NGF R, Nidogen-1, Nidogen-2, NKp30, NKp44, NKp46, NKp80, Nogo-A, Norrin, Notch-1, Notch-3, NOV, NPDC-1, NPTXR, NQO-1, Nrf2, NRG1-131, NSE, NTAL, NUDTS, Numb, NUP85, Olfactomedin-2, Olig2, OPG, OPN, OSCAR, OSM R beta, Osteoactivin, Osteoadherin, OX40, OX40 Ligand, P1GF-2, p2'7, p53, p63, PAI-1, PAPP-A, Pappalysin-2, PAR1, PARC, Pax3, PCK1, PCSK2, PD-1, PD-ECGF, PDGF R alpha, PDGF Rb, PDGF-AA, PDGF-AB, PDGF-CC, PD-L2, PDX-1, PEAR1, PECAM-1, Pentraxin 3, Pepsinogen II, Periostin, Persephin, PF4, PGRP-S, PIGF, PILR-alpha, Plexin A4, Plexin B3, Plexin D1, Podocalyxin, Podoplanin, POGLUT1, PON1, PRDX4, Pref-1, PRELP, Presenilin 1, Procalcitonin, Progranulin, proGRP, Prolactin, Prolactin R, PRX2, PSA-total, PSMA, PSMA1, PTH, PTH1R, PTP1B, PU.I, PYY, RAGE, RalA, RANK, RANTES, RBP4, RCOR1, Reg3A, Reg4, RELT, Renin, Resistin, Ret Midkine, RGM-A, RGM-B, RGM-C, ROBO2, ROBO3, ROBO4, ROR1, ROR2, R-Spondin 2, S100Al, S100A13, SALM4, SCCA2, SCF, SCF R, SDF-la, SDF-lb, Semaphorin 4C, Semaphorin 4D, Semaphorin 4G, Semaphorin 6A, Semaphorin 6B, Semaphorin 6C, Semaphorin 6D, Semaphorin 7A, Serpin A4, Serpin A5, Serpin B6, Serpin Fl, sFRP-3, SH2D1A, Shh-N, SHP-1, Siglec-10, Siglec-11, Siglec-2, Siglec-6, Siglec-7, Siglec-9, SIRP alpha, Sirtuin 1, Sirtuin 2, Sirtuin 5, SLAM, SLITRK5, Smad4, SMPD1, SorCS1, SorCS2, SorCS3, Sortilin, SOST, SOX15, SOX2, SOX7, SOX9, SP-D, SPHK1, Spinesin, SPINK1, SR-AI, SREC-I, SREC-11, ST3GAL1, ST6GAL 1, ST8SIA1, Stabilin-2, SUL T2A1, Syndecan-3, Syndecan-4, Syntaxin 4, Syntaxin 6, TACE, TAFA1, TAFA2, TAFAS, TARC, TAZ, TCN2, TC-PTP, TECK, Tenascin R, Testican 2, TFF3, TFPI, TFPI-2, TGFa, TGFb2, TGFb3 FOLR2, TGFbl, TGM3, TGM4, THAP 11, Thrombomodulin, Thrombospondin-2, Thrombospondin-5, THSD1, Thyroglobulin, Thyroid Peroxidase, Tie-1, Tie-2, TIM-1, TIM-3, TIMP-2, TLR1, TLR2, TLR3, TLR4, TNF R1, TNF RII, TNF4, TNFb, TPO, TPP1, TPST2, TRACP, TRAIL, TRAIL R1, TRAIL R3, TRAIL R4, TRANCE, Transferrin, TREM-1, TREM-2, TREML 1, TrkC, TROP-2, Troponin C, TROY, Trypsin 1, Trypsin 3, TSH, TSK, TSLP, TSLP R, TSP-1, TWEAKR, Ubiquitin+1, UCH-L3, ULBP-1, ULBP-2, ULBP-3, ULBP-4, UNC5H3, UNC5H4, uPA, uPAR, Uromodulin, VAMP-1, VAMP-2, VAP-A, VCAM-1, VE-Cadherin, VEGF R1, VEGF R2, VEGF R3, VEGF-C, Visfatin, vWF-A2, WIF-1, WISP-1, Wnt-4, XEDAR, and XIAP.

16 . The method of claim 14 , wherein the therapeutic bone marrow MSC secretome composition further comprises one or more of the following nucleic acids: hsa-let-7a-5p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7d-3p, hsa-let-7e-5p, hsa-let-7g-5p, hsa-let-7i, hsa-let-7i-5p, hsa-miR-100-5p, hsa-miR-103a-3p, hsa-miR-106a-5p, hsa-miR-106b-5p, hsa-mir-10b, hsa-miR-10b-5p, hsa-mir-1246, hsa-miR-1246, hsa-miR-125a-5p, hsa-miR-125b-5p, hsa-miR-130a-3p, hsa-miR-130b, hsa-miR-130b-3p, hsa-miR-132-3p, hsa-miR-136-5p, hsa-miR-138-5p, hsa-miR-139-5p, hsa-mir-140, hsa-miR-140-3p, hsa-miR-145-5p, hsa-mir-146a, hsa-miR-146a-5p, hsa-miR-148a-3p, hsa-miR-152-3p, hsa-miR-15a-5p, hsa-miR-15b-5p, hsa-mir-16-1, hsa-miR-16-2, hsa-miR-16-5p, hsa-miR-1'7-5p, hsa-miR-181a-5p, hsa-miR-191-5p, hsa-miR-193a-5p, hsa-miR-193b-3p, hsa-miR-19'7-3p, hsa-miR-199a-3p, hsa-miR-199a-5p, hsa-miR-199b-5p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, hsa-mir-203a, hsa-miR-203a-3p, hsa-miR-214-3p, hsa-mir-21, hsa-miR-21-3p, hsa-miR-21-5p, hsa-mir-221, hsa-miR-21-3p, hsa-mir-222, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-23a-3p, hsa-miR-23b-3p, hsa-mir-24-1, hsa-mir-24-2, hsa-miR-24-3p, hsa-mir-25, hsa-miR-25-3p, hsa-miR-26a-p, hsa-miR-27a-3p, hsa-mir-27b, hsa-miR-27b-3p, hsa-miR-29a-3p, hsa-miR-29c-3p, hsa-miR-30a-5p, hsa-miR-30a-5p, hsa-miR-30b-5p, hsa-miR-30c-5p, hsa-miR-30d, hsa-miR-30d-5p, hsa-mir-30e, hsa-miR-30e-5p, hsa-miR-3l-3p, hsa-miR-31-5p, hsa-miR-320a, hsa-miR-342-3p, hsa-miR-345-5p, hsa-miR-34a-5p, hsa-miR-361-5p, has-miR-376a-3p, hsa-miR-376c-3p, hsa-miR-423-3p, hsa-miR-423-5p, hsa-miR-424-5p, hsa-miR-484, hsa-mir-486-1, hsa-mir-486-2, hsa-miR-486-5p, hsa-miR-570-3p, hsa-miR-574-3p, hsa-miR-663a, hsa-miR-874-3p, hsa-mir-92a-1, hsa-mir-92a-2, hsa-miR-92a-3p, hsa-miR-92b-3p, hsa-mir-93, hsa-miR-93-5p, hsa-miR-940, hsa-miR-99a-5p, and has-miR-99b-5p.

17 . The method of claim 14 , wherein (i) the subject has been diagnosed with perianal fistula for at least six months, (ii) the subject has had at least one previous medical therapy within one year, or (iii) both (i) and (ii).

18 . The method of claim 17 , wherein the at least one previous medical therapy comprises one or more of: antibiotics, immunomodulators, monoclonal antibodies, small molecule inhibitors, or any combination thereof.

19 . A method of treating perianal fistula in a subject having Crohn's disease or ulcerative colitis, the method comprising administering to the subject a composition comprising a therapeutic bone marrow MSC secretome composition made by a method comprising:

(a) culturing bone marrow-derived MSCs under the following conditions to produce a bone marrow MSC conditioned media:

(i) oxygen tension below 5%; and

(ii) culture media having a pH below 7;

(b) harvesting the bone marrow MSC conditioned media; and

(c) formulating the bone marrow MSC conditioned media to produce the therapeutic bone marrow MSC secretome composition, wherein the therapeutic bone marrow MSC secretome composition comprises proteins and extracellular vesicles produced by the bone marrow-derived MSCs in (a).

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2025
From: PETTINE, KENNETH ALLEN
To: DIRECT BIOLOGICS, LLC
Reel/Frame 072925/0519 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2025
From: PETTINE, KENNETH ALLEN
To: DIRECT BIOLOGICS, LLC
Reel/Frame 071101/0740 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2025
From: MOSELEY, TIMOTHY ALEXANDER
To: DIRECT BIOLOGICS, LLC
Reel/Frame 071272/0718 →
Continuity (3)
Continuation PCTUS2024026444 · Apr 26, 2024
Provisional Application 63638807 · Apr 25, 2024
Related Publication 20250332200A1 · Oct 30, 2025
References Cited (400)
US 3610795A · Antoine et al. · 1971 [cited by applicant]
US 4897355A · Eppstein et al. · 1990 [cited by applicant]
US 5135917A · Burch et al. · 1992 [cited by applicant]
US 5712163A · Parenteau et al. · 1998 [cited by applicant]
US 6410588B1 · Feldmann et al. · 2002 [cited by applicant]
US 7029666B2 · Bruder et al. · 2006 [cited by applicant]
US 8021882B2 · Johnstone et al. · 2011 [cited by applicant]
US 8057789B2 · Hariri · 2011 [cited by applicant]
US 8372797B2 · Ichim · 2013 [cited by applicant]
US 8703710B2 · Dzau et al. · 2014 [cited by applicant]
US 8778416B2 · Cohen · 2014 [cited by applicant]
US 9408874B2 · Pettine · 2016 [cited by applicant]
US 9744130B2 · Lipp et al. · 2017 [cited by applicant]
US 9856455B2 · March et al. · 2018 [cited by applicant]
US 9980984B2 · Pettine · 2018 [cited by applicant]
US 10456425B2 · Herrera Sanchez et al. · 2019 [cited by applicant]
US 10744160B2 · Sokolov et al. · 2020 [cited by applicant]
US 10881693B2 · Alford · 2021 [cited by applicant]
US 11376283B2 · Sokolov et al. · 2022 [cited by applicant]
US 11529306B2 · Yi et al. · 2022 [cited by applicant]
US 12213995B2 · Pettine et al. · 2025 [cited by applicant]
US 12233092B2 · Aricha et al. · 2025 [cited by applicant]
US 20040248970A1 · Webster et al. · 2004 [cited by applicant]
US 20070254827A1 · Sutton et al. · 2007 [cited by applicant]
US 20080241112A1 · Westenfelder · 2008 [cited by applicant]
US 20090177487A1 · Eerkes · 2009 [cited by applicant]
US 20100178274A1 · Sekiya et al. · 2010 [cited by applicant]
US 20110003008A1 · Lim · 2011 [cited by applicant]
US 20110014251A1 · Ray · 2011 [cited by applicant]
US 20120064049A1 · Hunziker · 2012 [cited by applicant]
US 20130115198A1 · Hoffmann et al. · 2013 [cited by applicant]
US 20130129688A1 · Brenner et al. · 2013 [cited by applicant]
US 20130195899A1 · Ichim et al. · 2013 [cited by applicant]
US 20130210725A1 · Naughton et al. · 2013 [cited by applicant]
US 20130236427A1 · Pernock · 2013 [cited by applicant]
US 20140004601A1 · Lim · 2014 [cited by applicant]
US 20140065240A1 · Mitsialis et al. · 2014 [cited by applicant]
US 20140220053A1 · Muraca et al. · 2014 [cited by applicant]
US 20150086513A1 · Savkovic et al. · 2015 [cited by applicant]
US 20150125950A1 · Lim et al. · 2015 [cited by applicant]
US 20160113967A1 · Hedrick et al. · 2016 [cited by applicant]
US 20160263160A1 · Nolta et al. · 2016 [cited by applicant]
US 20160281045A1 · McCall et al. · 2016 [cited by applicant]
US 20170051359A1 · Pegtel et al. · 2017 [cited by applicant]
US 20170055561A1 · Naughton et al. · 2017 [cited by applicant]
US 20170107488A1 · Petcavich · 2017 [cited by applicant]
US 20170166864A1 · Kihm et al. · 2017 [cited by applicant]
US 20170189449A1 · Lim · 2017 [cited by applicant]
US 20170304368A1 · Marban et al. · 2017 [cited by applicant]
US 20180100149A1 · Marbán et al. · 2018 [cited by applicant]
US 20180214489A1 · Riordan · 2018 [cited by applicant]
US 20180242590A1 · Friedman · 2018 [cited by applicant]
US 20180264043A1 · Pettine et al. · 2018 [cited by applicant]
US 20180282762A1 · Gori · 2018 [cited by applicant]
US 20180318356A1 · Pettine et al. · 2018 [cited by applicant]
US 20180338866A1 · Kharazmi · 2018 [cited by applicant]
US 20190000886A1 · Ross · 2019 [cited by applicant]
US 20190015331A1 · Elliman et al. · 2019 [cited by applicant]
US 20190046576A1 · Gangaraju et al. · 2019 [cited by applicant]
US 20190133922A1 · Kang et al. · 2019 [cited by applicant]
US 20190195863A1 · Brivanlou et al. · 2019 [cited by applicant]
US 20190209665A1 · Pluchino et al. · 2019 [cited by applicant]
US 20190269739A1 · Brodie et al. · 2019 [cited by applicant]
US 20190328792A1 · Traweger et al. · 2019 [cited by applicant]
US 20190330594A1 · You et al. · 2019 [cited by applicant]
US 20200030253A1 · Kharazmi · 2020 [cited by applicant]
US 20200316226A1 · Marban et al. · 2020 [cited by applicant]
US 20200325452A1 · Alford · 2020 [cited by applicant]
US 20200360443A1 · Sokolov et al. · 2020 [cited by applicant]
US 20210000882A1 · Coronado · 2021 [cited by applicant]
US 20210030807A1 · Aricha et al. · 2021 [cited by applicant]
US 20210035368A1 · Schouela et al. · 2021 [cited by applicant]
US 20210038652A1 · Naughton et al. · 2021 [cited by applicant]
US 20210128627A1 · Aricha et al. · 2021 [cited by applicant]
US 20210169939A1 · Ilagan et al. · 2021 [cited by applicant]
US 20210196759A1 · Moseley et al. · 2021 [cited by applicant]
US 20210228643A1 · Bobis-Wozowicz et al. · 2021 [cited by applicant]
US 20210254056A1 · Liu et al. · 2021 [cited by applicant]
US 20210267892A1 · Machluf et al. · 2021 [cited by applicant]
US 20210299036A1 · Naughton · 2021 [cited by applicant]
US 20210348114A1 · Hudson et al. · 2021 [cited by applicant]
US 20210363525A1 · Saetrom et al. · 2021 [cited by applicant]
US 20210369617A1 · Alford · 2021 [cited by applicant]
US 20220000932A1 · Zhang et al. · 2022 [cited by applicant]
US 20220023347A9 · Mitsialis et al. · 2022 [cited by applicant]
US 20220079987A1 · Pettine · 2022 [cited by applicant]
US 20220079990A1 · Moseley et al. · 2022 [cited by applicant]
US 20220096560A1 · Mitsialis et al. · 2022 [cited by applicant]
US 20220110970A1 · Jhan et al. · 2022 [cited by applicant]
US 20220125848A1 · Pettine et al. · 2022 [cited by applicant]
US 20220136011A1 · Kalluri · 2022 [cited by applicant]
US 20220136053A1 · Pettine et al. · 2022 [cited by applicant]
US 20220151934A1 · Ridall et al. · 2022 [cited by applicant]
US 20220152151A1 · Pettine · 2022 [cited by applicant]
US 20220175843A1 · Westenfelder et al. · 2022 [cited by applicant]
US 20220195384A1 · Kim et al. · 2022 [cited by applicant]
US 20220195390A1 · Uzan et al. · 2022 [cited by applicant]
US 20220202871A1 · Pettine · 2022 [cited by applicant]
US 20220218755A1 · Ilagan et al. · 2022 [cited by applicant]
US 20220249699A1 · Guild et al. · 2022 [cited by applicant]
US 20220264872A1 · March et al. · 2022 [cited by applicant]
US 20220273725A1 · Ochiya · 2022 [cited by applicant]
US 20220387518A1 · Mishra et al. · 2022 [cited by applicant]
US 20230000954A1 · Alford et al. · 2023 [cited by applicant]
US 20230002476A1 · Alford et al. · 2023 [cited by applicant]
US 20230013636A1 · Kalluri · 2023 [cited by applicant]
US 20230105667A1 · Brodie · 2023 [cited by applicant]
US 20230142496A1 · Cheng · 2023 [cited by applicant]
US 20230143893A1 · Bird et al. · 2023 [cited by applicant]
US 20230159932A1 · Pettine · 2023 [cited by examiner]
US 20230172990A1 · Ohneda et al. · 2023 [cited by applicant]
US 20230181649A1 · Hariri et al. · 2023 [cited by applicant]
US 20230190818A1 · Jurga · 2023 [cited by applicant]
US 20230226267A1 · Madelska · 2023 [cited by applicant]
US 20230248773A1 · Jurga · 2023 [cited by applicant]
US 20230257712A1 · Jurga · 2023 [cited by examiner]
US 20230310507A1 · Lebovits et al. · 2023 [cited by applicant]
US 20230313144A1 · Yoshimura et al. · 2023 [cited by applicant]
US 20230313191A1 · Hicok et al. · 2023 [cited by applicant]
US 20240197832A1 · Hu et al. · 2024 [cited by applicant]
US 20250186501A1 · Pettine et al. · 2025 [cited by applicant]
US 20250277217A1 · Pettine et al. · 2025 [cited by applicant]
AU 2004203482A1 · 2004 [cited by applicant]
CA 2880404A1 · 2014 [cited by applicant]
CN 104622904A · 2015 [cited by applicant]
CN 108042572A · 2018 [cited by applicant]
CN 108498452A · 2018 [cited by applicant]
CN 111150743A · 2020 [cited by applicant]
CN 109718392B · 2021 [cited by applicant]
CN 118806794A · 2024 [cited by applicant]
EP 2533859A1 · 2012 [cited by applicant]
EP 2582791A2 · 2013 [cited by applicant]
EP 2687219A1 · 2014 [cited by applicant]
EP 2296672B1 · 2015 [cited by applicant]
EP 2683389B1 · 2017 [cited by applicant]
EP 2877187B1 · 2019 [cited by applicant]
EP 3492585A1 · 2019 [cited by applicant]
EP 3515474A1 · 2019 [cited by applicant]
EP 3568143A1 · 2019 [cited by applicant]
EP 3668319A1 · 2020 [cited by applicant]
EP 3672606A1 · 2020 [cited by applicant]
EP 3723773A1 · 2020 [cited by applicant]
EP 3402489B1 · 2021 [cited by applicant]
EP 3920889A1 · 2021 [cited by applicant]
EP 3952892A1 · 2022 [cited by applicant]
EP 4003305A1 · 2022 [cited by applicant]
EP 4069205A1 · 2022 [cited by applicant]
EP 4069826A1 · 2022 [cited by applicant]
EP 4132546A2 · 2023 [cited by applicant]
EP 4146247A1 · 2023 [cited by applicant]
EP 4178591A1 · 2023 [cited by applicant]
EP 4180050A1 · 2023 [cited by applicant]
EP 4181935A1 · 2023 [cited by applicant]
JP 2008544957A · 2008 [cited by applicant]
JP 2016065106A · 2016 [cited by applicant]
JP 2017180553A · 2017 [cited by applicant]
JP 2018538132A · 2018 [cited by applicant]
JP WO2019235362A1 · 2021 [cited by applicant]
JP 2024524472A · 2024 [cited by applicant]
KR 20180023865A · 2018 [cited by applicant]
KR 20180127280A · 2018 [cited by applicant]
WO WO03051331A1 · 2003 [cited by applicant]
WO WO2006036213A2 · 2006 [cited by applicant]
WO WO2006071011A1 · 2006 [cited by applicant]
WO WO2009105044A1 · 2009 [cited by applicant]
WO WO2009150199A1 · 2009 [cited by applicant]
WO WO2012061537A2 · 2012 [cited by applicant]
WO WO2012125471A1 · 2012 [cited by applicant]
WO WO2012142569A2 · 2012 [cited by applicant]
WO WO2012174282A2 · 2012 [cited by applicant]
WO WO2013006327A1 · 2013 [cited by applicant]
WO WO2013090523A2 · 2013 [cited by applicant]
WO WO2013150303A1 · 2013 [cited by applicant]
WO WO2013159091A2 · 2013 [cited by applicant]
WO WO2014005183A1 · 2014 [cited by applicant]
WO WO2015031110A2 · 2015 [cited by applicant]
WO WO2015048842A1 · 2015 [cited by applicant]
WO WO2016082882A1 · 2016 [cited by applicant]
WO WO2016149358A1 · 2016 [cited by applicant]
WO WO2016156865A1 · 2016 [cited by applicant]
WO WO2017001649A1 · 2017 [cited by applicant]
WO WO2017023689A1 · 2017 [cited by applicant]
WO WO2017076924A1 · 2017 [cited by applicant]
WO WO2017117585A1 · 2017 [cited by applicant]
WO WO2017122095A1 · 2017 [cited by applicant]
WO WO2017123022A1 · 2017 [cited by applicant]
WO WO2017139795A1 · 2017 [cited by applicant]
WO WO2017196798A1 · 2017 [cited by applicant]
WO WO2017218846A1 · 2017 [cited by applicant]
WO WO2018038575A1 · 2018 [cited by applicant]
WO WO2018078524A1 · 2018 [cited by applicant]
WO WO2018083700A1 · 2018 [cited by applicant]
WO WO2018102696A1 · 2018 [cited by applicant]
WO WO2018130554A1 · 2018 [cited by applicant]
WO WO2018131003A1 · 2018 [cited by applicant]
WO WO2018131900A2 · 2018 [cited by applicant]
WO WO2018144637A1 · 2018 [cited by applicant]
WO WO2018150440A1 · 2018 [cited by applicant]
WO WO2018162696A1 · 2018 [cited by applicant]
WO WO2018204889A1 · 2018 [cited by applicant]
WO WO2018208670A1 · 2018 [cited by applicant]
WO WO2018211510A1 · 2018 [cited by applicant]
WO WO2018226758A2 · 2018 [cited by applicant]
WO WO2019035880A1 · 2019 [cited by applicant]
WO WO2019040896A1 · 2019 [cited by applicant]
WO WO2019099955A1 · 2019 [cited by applicant]
WO WO2019118817A1 · 2019 [cited by applicant]
WO WO2019143847A1 · 2019 [cited by applicant]
WO WO2019152522A1 · 2019 [cited by applicant]
WO WO2019161590A1 · 2019 [cited by applicant]
WO WO2019217091A1 · 2019 [cited by applicant]
WO WO2019222170A1 · 2019 [cited by applicant]
WO WO2019231562A1 · 2019 [cited by applicant]
WO WO2019235362A1 · 2019 [cited by applicant]
WO WO2020021312A1 · 2020 [cited by applicant]
WO WO2020030750A1 · 2020 [cited by applicant]
WO WO2020061408A1 · 2020 [cited by applicant]
WO WO2020081859A1 · 2020 [cited by applicant]
WO WO2020139975A1 · 2020 [cited by applicant]
WO WO2020142769A1 · 2020 [cited by applicant]
WO WO2020160342A1 · 2020 [cited by applicant]
WO WO2020163705A1 · 2020 [cited by applicant]
WO WO2020163803A1 · 2020 [cited by applicant]
WO WO2020172270A1 · 2020 [cited by applicant]
WO WO2020182938A1 · 2020 [cited by applicant]
WO WO2020210248A1 · 2020 [cited by applicant]
WO WO2020223349A1 · 2020 [cited by applicant]
WO WO2020230954A1 · 2020 [cited by applicant]
WO WO2020251181A1 · 2020 [cited by applicant]
WO WO2020257720A1 · 2020 [cited by applicant]
WO WO2021009660A1 · 2021 [cited by applicant]
WO WO2021011935A1 · 2021 [cited by applicant]
WO WO2021016368A1 · 2021 [cited by applicant]
WO WO2021016727A1 · 2021 [cited by applicant]
WO WO2021113299A1 · 2021 [cited by applicant]
WO WO2021113761A1 · 2021 [cited by applicant]
WO WO2021147923A1 · 2021 [cited by applicant]
WO WO2021177473A1 · 2021 [cited by applicant]
WO WO2021181399A1 · 2021 [cited by applicant]
WO WO2021195154A1 · 2021 [cited by applicant]
WO WO2021207282A2 · 2021 [cited by applicant]
WO WO2021216903A1 · 2021 [cited by applicant]
WO WO2021221471A1 · 2021 [cited by applicant]
WO WO2021226108A1 · 2021 [cited by applicant]
WO WO2021262879A1 · 2021 [cited by applicant]
WO WO2022008654A1 · 2022 [cited by applicant]
WO WO2022008657A1 · 2022 [cited by applicant]
WO WO2022018729A1 · 2022 [cited by applicant]
WO WO2022050373A1 · 2022 [cited by applicant]
WO WO2022076419A1 · 2022 [cited by applicant]
WO WO2022096708A1 · 2022 [cited by applicant]
WO WO2022150696A1 · 2022 [cited by applicant]
WO WO2022150839A1 · 2022 [cited by applicant]
WO WO2022174079A1 · 2022 [cited by applicant]
WO WO2022190091A1 · 2022 [cited by applicant]
WO WO2022251167A2 · 2022 [cited by applicant]
WO WO2022261636A1 · 2022 [cited by applicant]
WO WO2022265864A2 · 2022 [cited by applicant]
WO WO2022266399A1 · 2022 [cited by applicant]
WO WO2023004087A2 · 2023 [cited by applicant]
WO WO2023275164A1 · 2023 [cited by applicant]
WO WO2023278883A1 · 2023 [cited by applicant]
WO WO2023281524A1 · 2023 [cited by applicant]
WO WO2023282424A1 · 2023 [cited by applicant]
WO WO2023021525A1 · 2023 [cited by applicant]
WO WO2023024637A1 · 2023 [cited by applicant]
WO WO2023033500A1 · 2023 [cited by applicant]
WO WO2023064555A1 · 2023 [cited by applicant]
WO WO2023075557A1 · 2023 [cited by applicant]
WO WO2023082012A1 · 2023 [cited by applicant]
WO WO2023091904A1 · 2023 [cited by applicant]
WO WO2023123216A1 · 2023 [cited by applicant]
WO WO2023127645A1 · 2023 [cited by applicant]
WO WO2023164241A1 · 2023 [cited by applicant]
WO WO2023192916A2 · 2023 [cited by applicant]
WO WO2023200882A1 · 2023 [cited by applicant]
WO WO2024030909A1 · 2024 [cited by applicant]
WO WO2024192119A1 · 2024 [cited by applicant]
WO WO2024254459A2 · 2024 [cited by applicant]
WO WO2024254540A2 · 2024 [cited by applicant]
WO WO2025101653A1 · 2025 [cited by applicant]
WO WO2025101658A1 · 2025 [cited by applicant]
WO WO2025101659A1 · 2025 [cited by applicant]
WO WO2025101663A1 · 2025 [cited by applicant]
360 Health Alert Newsletter: 2023 Research: Advanced use of Extracellular Vesicles for Today's Top Chronic Disorders (2023). [cited by applicant]
Aatonen, Maria. et al. Isolation and Characterization of Platelet-derived Extracellular Vesicles. Journal of Extracellular Vesicles 3:1-15 (2014). [cited by applicant]
Abraham et al.: Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 9(1):28-38 (2019). [cited by applicant]
Aggarwal, Sudeepta. et al. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815-1822 (2005). [cited by applicant]
Alam et al., An osteopontin-derived peptide inhibits human hair growth at least in part by decreasing fibroblast growth factor-7 production in outer root sheath keratinocytes. Br J Dermatol 182(6):1404-1414 (2020). [cited by applicant]
Alipoor, Shamila D. et al. Exosomes and Exosomal miRNA in Respiratory Diseases. Mediators Inflamm 2016:5628404, 1-11 (2016). [cited by applicant]
Allison, Malorye. Genzyme backs Osiris, despite Prochymal flop. Nature Biotechnology 27(11):966-967 (2009). [cited by applicant]
Anderson, Monique R. et al. Exosomes in Viral Disease. Neurotherapeutics 13(3):535-546 (2016). [cited by applicant]
Arima, Ken. et al. Autologous Transplantation of Bone Marrow Mononuclear Cells Improved Ischemic Peripheral Neuropathy in Humans. Journal of the American College of Cardiology 56(3):238-239 (2010). [cited by applicant]
Attur, Mukundan et al. Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. Annals of the rheumatic diseases 79(3):400-407 (2020). Pu… [cited by applicant]
Atwell, Karina. et al. Diagnosis and Management of Hypermobility Spectrum Disorders in Primary Care. The Journal of the American Board of Family Medicine 34(4):838-848 (2021). [cited by applicant]
Aversa et al., Platelet-derived growth factor (PDGF) and PDGF receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. J Endocrinol. 170(2):395-402 (2001). [cited by applicant]
Baberg, Falk. et al. Secretome analysis of human bone marrow derived mesenchymal stromal cells. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1867(4):434-441 (2019). [cited by applicant]
Backlund, Lena. et al. Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar disorders 13(5-6):500-508 (2011). [cited by applicant]
Bagshawe, K. D., et al. A cytotoxic agent can be generated selectively at cancer sites. British Journal of Cancer 58(6):700-703 (1988). [cited by applicant]
Bagshawe, K. D. Towards generating cytotoxic agents at cancer sites. The First Bagshawe Lecture. Br. J. Cancer 60:275-281 (1989). [cited by applicant]
Ball et al., Arthroscopic treatment of post-traumatic elbow contracture. Journal of Shoulder and Elbow Surgery 11(6):624-629 (2002). [cited by applicant]
Barbash, Israel M. et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 108(7):863-868 (2003). [cited by applicant]
Bari et al.: Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells. 9(924):1-5 (2020). [cited by applicant]
Barnett, J H, and J W Smoller. The genetics of bipolar disorder. Neuroscience 164(1):331-343 (2009). [cited by applicant]
Barnhoorn, Marieke C. et al. Long-term Evaluation of Allogeneic Bone Marrow-derived Mesenchymal Stromal Cell Therapy for Crohn's Disease Perianal Fistulas. Journal of Crohn's and Colitis 14(1):64-70 (2020). [cited by applicant]
Bartaula-Brevik et al.: Secretome of Mesenchymal Stem Cells Grown in Hypoxia Accelerates Wound Healing and Vessel Formation In Vitro. International Journal of Stem Cell Research and Therapy. 4(1):1-9 (2017). [cited by applicant]
Bartholomew, Amelia. et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30(1): 42-48 (2002). [cited by applicant]
Bassir, Seyed Hossein et al. Potential for Stem Cell-based Periodontal Therapy. Journal of Cellular Physiology 231(1):50-61 (2016). [cited by applicant]
Batch et al., Identification and localization of insulin-like growth factor-binding protein (IGFBP) messenger RNAs in human hair follicle dermal papilla. J Invest Dermatol. 106(3):471-475 (1996). [cited by applicant]
Battelli et al., T lymphocyte killing by a xanthine-oxidase-containing immunotoxin. Cancer Immunology, Immunotherapy 35(6):421-425 (1992). [cited by applicant]
Behr, Luc. et al. Intra renal arterial injection of autologous mesenchymal stem cells in an ovine model in the postischemic kidney. Nephron Physiology 107(3):p. 65-p. 76 (2007). [cited by applicant]
Beitzel et al., The future role of mesenchymal stem cells in the management of shoulder disorders. Arthroscopy 29(10):1702-1711 (2013). [cited by applicant]
Bender et al.: Intra-Articular Injection of an Extracellular Vesicle Isolate to Treat Shoulder Osteoarthritis in an Athlete. J Regen Biol Med. 2(1):1-6 (2020). [cited by applicant]
Bender et al.: Treatment of Elbow Arthritis with a Bone Marrow derived Mesenchymal Stem Cell Extracellular Vesicle Isolate Product. J Orthop Study Sports Med. 1(1):1-6 (2021). [cited by applicant]
Bertolini et al., Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS ONE. 9:e94260 (2014). [cited by applicant]
Bisaga et al., The use of mesenchymal stem cells in optic nerve atrophy in patients with multiple sclerosis: a pilot study. Annals of Clinical and Experimental Neurology 11(2):201 [2201] (2017). [cited by applicant]
Biswas et al., Primary and secondary arthritis of the elbow. Arthritis. May 27, 2013, (2013). [cited by applicant]
Black et al., Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet… [cited by applicant]
Black et al., Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther. 9:192-200 (2008). [cited by applicant]
Bligh, Richard, and Robert Besancenez. Safety and Efficacy of Bone Marrow Mesenchymal Stem Cell Extracellular Vesicles in Long COVID Patients: A Case Series. Journal of Stem Cells Research Development & Therapy 10(1):10… [cited by applicant]
Bligh: Treatment of Idiopathic Pulmonary Fibrosis With an Extracellular Vesicle Isolate Product. International Journal of Science and Research Archive. 02(02):231-236 (2021). [cited by applicant]
Blood and Marrow Stem Cell Transplantation. Leukemia & Lymphoma Society Retrieved from Internet URL: http://www.lls.org/resource-center/download-or-order-free-publications. Accessed on Jul. 8, 2016. [cited by applicant]
Bonovas, Stefanos et al. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 14(10):1385-1397.e1… [cited by applicant]
Boraschi CA, IL-18 in autoimmunity: review. Eur Cytokine Netw. 17:224-252 (2006). [cited by applicant]
Botchkarev et al., Edar signaling in the control of hair follicle development. J Investig Dermatol Symp Proc. 10(3):247-251 (2005). [cited by applicant]
Bracho-Sanchez, Evelyn. et al. Suppression of local inflammation via galectin-anchored indoleamine 2, 3-dioxygenase. Nature biomedical engineering 7(9):1156-1169 (2023). [cited by applicant]
Brigham et al. Expression of a prokaryotic gene in cultured lung endothelial cells after lipofection with a plasmid vector. Am. J. Resp. Cell. Mol. Biol. 1:95-100 (1989). [cited by applicant]
Brock, Isabelle. et al. Mast Cell Activation Disease and Immunoglobulin Deficiency in Patients With Hypermobile Ehlers-danlos Syndrome/hypermobility Spectrum Disorder. American Journal of Medical Genetics Part C: Semina… [cited by applicant]
Brown et al., Molecular and cellular mechanisms of receptor-mediated endocytosis. DNA and Cell Biology 10(6):399-409 (1991). [cited by applicant]
Bruno, Stefania. et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. Journal of the American Society of Nephrology 20(5):1053-1067 (2009). [cited by applicant]
Budhiparama, Nicolaas C. et al. The role of genetic polymorphisms of interleukin-1 (IL-1R1 and IL-1RN) in primary knee osteoarthritis in Indonesia. Scientific reports 13(1):7967, 1-10 (2023). [cited by applicant]
Burian, Egon. et al. Effect of hypoxia on the proliferation of porcine bone marrow-derived mesenchymal stem cells and adipose-derived mesenchymal stem cells in 2- and 3-dimensional culture. Journal of cranio-maxillo-fac… [cited by applicant]
Burnett et al., GGF2 is neuroprotective in a rat model of cavernous nerve injury-induced erectile dysfunction. J Sex Med. 12(4):897-905 (2015). [cited by applicant]
Bustos, Martha L. et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem cells translational medicine 2(11):884-895… [cited by applicant]
Cabana: An Update on Exosomes. Aesthetic Authority. Technology Pipeline: Aestic Authority 2(1):22 (2020) https://www.dermatologytimes.com/view/an-update-on-exosomes. [cited by applicant]
Cai et al., Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells 25(12):3234-3243 (2007). [cited by applicant]
Cai, L. et al. A slow release formulation of insulin as a treatment for osteoarthritis. Osteoarthritis and Cartilage 10(9):692-706 (2002). [cited by applicant]
Cai, Yu. et al. Anti-inflammatory and chondroprotective effects of platelet-derived growth factor-BB on osteoarthritis rat models. The Journals of Gerontology: Series A 78(1):51-59 (2023). [cited by applicant]
Cao, Yantian. et al. Efficacy of Stem Cells Therapy for Crohn's Fistula: a Meta-analysis and Systematic Review. Stem Cell Research and Therapy 12(1):32, 1-11 (2021). [cited by applicant]
Caplan et al., Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:1076-1084 (2006). [cited by applicant]
Caplan et al., The MSC: an injury drugstore. Cell Stem Cell 9(1):11-5 (2011). [cited by applicant]
Carneiro et al., Emerging role for TNF-a in erectile dysfunction. J Sex Med. 7(12):3823-3834 (2010). [cited by applicant]
Caron, Benedicte. et al. Endpoints for Perianal Crohn's Disease Trials: past, present and future. Journal of Crohn's and Colitis 15(8):1387-1398 (2021). [cited by applicant]
Celik et al., Genetic analysis of interleukin 18 gene polymorphisms in alopecia areata. J Clin Lab Anal. 32(5):e22386 (2018). [cited by applicant]
Centeno: Exosomes, Mary Kaye, and Pink Caddys (2019) https://regenexx.com/blog/direct-biologics-exosomes/. [cited by applicant]
Centers for Disease Control and Prevention (CDC) Prevalence and most common causes of disability among adults—United States, 2005. Morbidity and Mortality Weekly Report 58(16):421-426 (2009). [cited by applicant]
Chambaz, Marion. et al. Deep Remission on Magnetic Resonance Imaging Impacts Outcomes of Perianal Fistulizing Crohn's Disease. Digestive and Liver Disease 51(3):358-363 (2019). [cited by applicant]
Chang et al., Exosomes and stem cells in degenerative disease diagnosis and therapy. Cell Transplantation 27(3):349-363 (2018). [cited by applicant]
Chang et al., Tissue engineering based cartilage repair with mesenchymal stem cells in a porcine model. J Orthop Res 29:1874-1880 (2011). [cited by applicant]
Chang, Shannon. et al. A Review of Available Medical Therapies to Treat Moderate-to-Severe Inflammatory Bowel Disease. Am J Gastroenterol 119(1):55-80 (2024). Published Online Aug. 24, 2023. [cited by applicant]
Chen et al., Regenerative hair waves in aging mice and extra-follicular modulators follistatin, dkkl, and sfrp4. J Invest Dermatol. 134(8):2086-2096 (2014). [cited by applicant]
Chen, George L. et al. Remestemcel-L for Acute Graft-versus-host Disease Therapy. Expert Opinion on Biological Therapy 14(2):261-269 (2014). [cited by applicant]
Chen, Lei. et al. Pre-vascularization Enhances Therapeutic Effects of Human Mesenchymal Stem Cell Sheets in Full Thickness Skin Wound Repair. Theranostics 7(1):117-131 (2017). [cited by applicant]
Chen, Liang-Yun. et al. Frontier Review of the Molecular Mechanisms and Current Approaches of Stem Cell-derived Exosomes. Cells 12(7):1018, 1-29 (2023). [cited by applicant]
Chen, Liwen. et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS one 3(4):e1886, 1-12 (2008). [cited by applicant]
Cheng, Daye. et al. The relationship between interleukin-18 polymorphisms and allergic disease: a meta-analysis. BioMed Research International 2014(1):290687, 1-11 (2014). [cited by applicant]
Cheng et al., Focus on mesenchymal stem cell-derived exosomes: opportunities and challenges in cell-free therapy. Stem Cells Int. 2017:6305295 (2017). [cited by applicant]
Chew et al., Mesenchymal stem cell exosomes enhance periodontal ligament cell functions and promote periodontal regeneration. Acta Biomater 15:89:252-264 (2019). [cited by applicant]
Chew et al., Mesenchymal stem cells in human meniscal regeneration: a systemic review. Ann Med Surg. 24:3-7 (2017). [cited by applicant]
Chia, Shi-Lu. et al. Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis & rheumatism: official Journal of the… [cited by applicant]
Chinese Clinical Trial Registry ChiCTR2000030261. A Study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus phnumonia (COVID019). Record Version as of Feb. 26, 2… [cited by applicant]
Ching-Ping et al.: Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. Clinical science. 124(3):165-176 (2012). [cited by applicant]
Cho, Yong Beom. et al. Autologous adipose tissue-derived stem cells for the treatment of Crohn's fistula: a phase I clinical study. Cell Transplant 22(2):279-285 (2013) Published online Sep. 21, 2012. [cited by applicant]
Cho, Yong Beom. et al. Long-term results of adipose-derived stem cell therapy for the treatment of Crohn's fistula. Stem Cells Transl Med 4(5):532-537 (2015). [cited by applicant]
Choi et al., Exosomes secreted by human adipose-derived stem cells regulate the expression of collagen synthesis—related genes in human dermal fibroblasts. Abstract Book: ISEV2017, Journal of Extracellular Vesicles 6:su… [cited by applicant]
Ciavarella, Sabino. et al. A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression. Stem cells and development 24(12… [cited by applicant]
Ciccocioppo et al., Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60(6):788-798 (2011). [cited by applicant]
Clinical Trial No. NCT04493242. Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS. https://clinicaltrials.gov/study/NCT04493242 (Jul. 29, 2020). [cited by applicant]
Clinical Trial No. NCT04657458. Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS. https://clinicaltrials.gov/study/NCT04657458 (Dec. 7, 2020). [cited by applicant]
Clinical Trial No. NCT05116761. ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome. https://clinicaltrials.gov/study/NCT05116761 (Nov. 9, 2021). [cited by applicant]
Clinical Trial No. NCT05125562. Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19. https://clinicaltrials.gov/study/NCT05125562 (Nov. 16, 2021). [cited by applicant]
Clinical Trial No. NCT05127122. Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS. https://clinicaltrials.gov/study/NCT05127122 (Nov. 9, 2021). [cited by applicant]
Clinical Trial No. NCT05130983. Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease. https://clinicaltrials.gov/study/NCT05130983 (Nov. 16, 2021). [cited by applicant]
Clinical Trial No. NCT05176366. Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis. https://clinicaltrials.gov/study/NCT05176366 (Dec. 14, 2021). [cited by applicant]
Clinical Trial No. NCT05215288. Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients https://clinicaltrials.gov/study/NCT05215288 (Jan. 18, 2022). [cited by applicant]
Clinical Trial No. NCT05354141. Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (Extinguish ARDS). https://clinicaltrials.gov/study/NCT05354141 (Apr. 22, 2022). [cited by applicant]
Clinical Trial No. NCT05836883. Study of ExoFlo for the Treatment of Perianal Fistulas. https://clinicaltrials.gov/study/NCT05836883 (Apr. 19, 2023). [cited by applicant]
Colombel, Jean-Frédéric. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132(1):52-65 (2007) Published online Nov. 29, 2006. [cited by applicant]
Colombo, M. et al., “Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles.” Annu Rev Cell Dev Biol, 2014, 30:255-289. [cited by applicant]
Conese et al.: Paracrine Effects and Heterogeneity of Marrow-Derived Stem/Progenitor Cells: Relevance for the Treatment of Respiratory Diseases. Cells Tissues Organs. 197:445-473 (2013). [cited by applicant]
Cook, Andrew D. et al. Granulocyte-macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis pain and disease development. Arthritis research & therapy 14(5):R199, 1-9 (2012). [cited by applicant]
Co-pending Appl. Serial No. PCT/US2019/026595 Application as Filed Apr. 9, 2019. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2019/068615 Application as Filed Dec. 26, 2019. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/012359 Application as Filed Jan. 6, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/015982 Application as Filed Jan. 30, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/017341 Application as Filed Feb. 7, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/018821 Application as Filed Feb. 19, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/030476 Application as Filed Apr. 29, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2020/042762 Application as Filed Jul. 20, 2020. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2021/028686 Application as Filed Apr. 22, 2021. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2023/065115 Application as Filed Mar. 29, 2023. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2024/019725 Application as Filed Mar. 13, 2024. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2024/026444 Application as Filed Apr. 26, 2024. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2024/033022 Application as Filed Jun. 7, 2024. [cited by applicant]
Co-pending Appl. Serial No. PCT/US2024/033123 Application as Filed Jun. 7, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 17/059,874 Claims as of May 7, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 17/418,342 Claims as of May 21, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 17/420,500 Claims as of Jun. 13, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 17/427,192 Claims as of Jun. 13, 2024. [cited by applicant]
Co-pending U.S. Appl. No. 17/429,553 Claims as of Aug. 9, 2021. [cited by applicant]